$TOVX
Theriva Biologics, Inc.

2015 Q1 Form 10-Q Financial Statement

#000114420415029365 Filed on May 11, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.710M $1.120M
YoY Change 52.68% 0.0%
% of Gross Profit
Research & Development $6.494M $2.717M
YoY Change 139.01% 143.02%
% of Gross Profit
Depreciation & Amortization $8.000K $3.000K
YoY Change 166.67% -72.73%
% of Gross Profit
Operating Expenses $8.207M $3.839M
YoY Change 113.78% 71.38%
Operating Profit -$8.207M -$3.839M
YoY Change 113.78%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$4.151M $1.000K
YoY Change -415200.0% -91.67%
Pretax Income -$8.207M -$3.839M
YoY Change 113.78% 71.38%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$12.36M -$3.838M
YoY Change 222.02% 72.26%
Net Earnings / Revenue
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$0.17 -$2.299M
COMMON SHARES
Basic Shares Outstanding 72.67M shares 58.28M shares
Diluted Shares Outstanding 72.67M shares

Balance Sheet

Concept 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.05M $11.16M
YoY Change 7.97% 30.99%
Cash & Equivalents $12.05M $11.16M
Short-Term Investments
Other Short-Term Assets $1.574M $1.332M
YoY Change 18.17% -39.18%
Inventory
Prepaid Expenses $374.0K $48.00K
Receivables
Other Receivables
Total Short-Term Assets $13.62M $12.49M
YoY Change 9.1% 9.06%
LONG-TERM ASSETS
Property, Plant & Equipment $75.00K $38.00K
YoY Change 97.37% -82.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $10.00K
YoY Change 100.0% -50.0%
Total Long-Term Assets $93.00K $44.00K
YoY Change 111.36% -80.87%
TOTAL ASSETS
Total Short-Term Assets $13.62M $12.49M
Total Long-Term Assets $93.00K $44.00K
Total Assets $13.72M $12.53M
YoY Change 9.46% 7.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.559M $773.0K
YoY Change 101.68% 286.5%
Accrued Expenses $2.646M $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.34M $773.0K
YoY Change 1884.61% 286.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $15.34M $773.0K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $15.34M $773.0K
YoY Change 1884.61% 286.5%
SHAREHOLDERS EQUITY
Retained Earnings -$113.4M -$85.10M
YoY Change 33.26%
Common Stock $111.8M $96.85M
YoY Change 15.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.625M $11.76M
YoY Change
Total Liabilities & Shareholders Equity $13.72M $12.53M
YoY Change 9.46% 7.29%

Cashflow Statement

Concept 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$12.36M -$3.838M
YoY Change 222.02% 72.26%
Depreciation, Depletion And Amortization $8.000K $3.000K
YoY Change 166.67% -72.73%
Cash From Operating Activities -$5.458M -$3.470M
YoY Change 57.29% 109.04%
INVESTING ACTIVITIES
Capital Expenditures $18.00K $4.000K
YoY Change 350.0% 33.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$18.00K -$4.000K
YoY Change 350.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 $4.000K
YoY Change -100.0% -98.26%
NET CHANGE
Cash From Operating Activities -$5.458M -$3.470M
Cash From Investing Activities -$18.00K -$4.000K
Cash From Financing Activities $0.00 $4.000K
Net Change In Cash -$5.476M -$3.470M
YoY Change 57.81% 142.66%
FREE CASH FLOW
Cash From Operating Activities -$5.458M -$3.470M
Capital Expenditures $18.00K $4.000K
Free Cash Flow -$5.476M -$3.474M
YoY Change 57.63% 108.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
73179307 shares
CY2015Q1 dei Trading Symbol
TradingSymbol
SYN
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12049000 USD
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1574000 USD
CY2015Q1 us-gaap Assets Current
AssetsCurrent
13623000 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000 USD
CY2015Q1 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
18000 USD
CY2015Q1 us-gaap Assets
Assets
13716000 USD
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1559000 USD
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2646000 USD
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15341000 USD
CY2015Q1 us-gaap Liabilities
Liabilities
15341000 USD
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
73000 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
72000 USD
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
111702000 USD
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
110526000 USD
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-113400000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101042000 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
-1625000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
9556000 USD
CY2015Q1 us-gaap Minority Interest
MinorityInterest
0 USD
CY2014Q4 us-gaap Minority Interest
MinorityInterest
0 USD
CY2015Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1625000 USD
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9556000 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13716000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19144000 USD
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000894158
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1548000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
19073000 USD
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
Synthetic Biologics, Inc.
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17525000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65000 USD
CY2014Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
6000 USD
CY2014Q4 us-gaap Assets
Assets
19144000 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
996000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1298000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9588000 USD
CY2014Q4 us-gaap Liabilities
Liabilities
9588000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
631000 USD
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72725987 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72594626 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72807469 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72513144 shares
CY2015Q1 syn Prepaid Expenses Research And Development
PrepaidExpensesResearchAndDevelopment
1060000 USD
CY2014Q4 syn Prepaid Expenses Research And Development
PrepaidExpensesResearchAndDevelopment
1067000 USD
CY2015Q1 us-gaap Prepaid Insurance
PrepaidInsurance
140000 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
7029808 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares
CY2014 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
232619 shares
CY2015Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
454896 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.88
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.8
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7974794 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.99
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.75
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2014 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
1.47
CY2015Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2014Q4 us-gaap Prepaid Insurance
PrepaidInsurance
228000 USD
CY2015Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
374000 USD
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
253000 USD
CY2015Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1574000 USD
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1548000 USD
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
122000 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
104000 USD
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
47000 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
39000 USD
CY2015Q1 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
74000 USD
CY2014Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
247000 USD
CY2015Q1 syn Accrued Vendor Payments
AccruedVendorPayments
225000 USD
CY2014Q4 syn Accrued Vendor Payments
AccruedVendorPayments
176000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.26 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.31 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0157 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0203 pure
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2014Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
CY2015Q1 syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1632501 shares
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1122000 USD
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1713000 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2717000 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6494000 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
3839000 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
8207000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3839000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8207000 USD
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 USD
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4151000 USD
CY2014Q1 us-gaap Profit Loss
ProfitLoss
-3838000 USD
CY2015Q1 us-gaap Profit Loss
ProfitLoss
-12358000 USD
CY2014Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2015Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-3838000 USD
CY2014Q4 syn Warrant Liabilities
WarrantLiabilities
6756000 USD
CY2015Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
228000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-12358000 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58324260 shares
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
72673959 shares
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
362000 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
827000 USD
CY2014Q1 us-gaap Depreciation
Depreciation
3000 USD
CY2015Q1 us-gaap Depreciation
Depreciation
8000 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-259000 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
26000 USD
CY2014Q1 syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
2000 USD
CY2015Q1 syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
12000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
563000 USD
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 USD
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1348000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3470000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5458000 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18000 USD
CY2014Q1 syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
4000 USD
CY2015Q1 syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
0 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2014Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-3470000 USD
CY2015Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-5476000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14625000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11155000 USD
CY2014Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2015Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2015Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2015Q1 syn Warrant Liabilities
WarrantLiabilities
10908000 USD
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
538000 USD
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2015Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4152000 USD
CY2014Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-885000 USD
CY2015Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-310000 USD
CY2015Q1 syn Accrued Milestone Payable
AccruedMilestonePayable
1000000 USD
CY2014Q4 syn Accrued Milestone Payable
AccruedMilestonePayable
350000 USD
CY2015Q1 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
1347000 USD
CY2014Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
525000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.07
CY2015Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.17
CY2014Q1 syn Stock Issued For Milestone Payments
StockIssuedForMilestonePayments
0 USD
CY2015Q1 syn Stock Issued For Milestone Payments
StockIssuedForMilestonePayments
-350000 USD
CY2015Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
316522 shares

Files In Submission

Name View Source Status
0001144204-15-029365-index-headers.html Edgar Link pending
0001144204-15-029365-index.html Edgar Link pending
0001144204-15-029365.txt Edgar Link pending
0001144204-15-029365-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20150331.xml Edgar Link completed
syn-20150331.xsd Edgar Link pending
syn-20150331_cal.xml Edgar Link unprocessable
syn-20150331_def.xml Edgar Link unprocessable
syn-20150331_lab.xml Edgar Link unprocessable
syn-20150331_pre.xml Edgar Link unprocessable
v409108_10q.htm Edgar Link pending
v409108_ex31-1.htm Edgar Link pending
v409108_ex31-2.htm Edgar Link pending
v409108_ex32-1.htm Edgar Link pending
v409108_ex32-2.htm Edgar Link pending